A Systematic Review of Biosynthesized Metallic Nanoparticles as a Promising Anti-Cancer-Strategy
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Cancer is one of the foremost causes of death worldwide. Cancer develops because of mutation in genes that regulate normal cell cycle and cell division, thereby resulting in uncontrolled division and proliferation of cells. Various drugs have been used to treat cancer thus far; however, conventional chemotherapeutic drugs have lower bioavailability, rapid renal clearance, unequal delivery, and severe side effects. In the recent years, nanotechnology has flourished rapidly and has a multitude of applications in the biomedical field. Bio-mediated nanoparticles (NPs) are cost effective, safe, and biocompatible and have got substantial attention from researchers around the globe. Due to their safe profile and fewer side effects, these nanoscale materials offer a promising cure for cancer. Currently, various metallic NPs have been designed to cure or diagnose cancer; among these, silver (Ag), gold (Au), zinc (Zn) and copper (Cu) are the leading anti-cancer NPs. The anticancer potential of these NPs is attributed to the production of reactive oxygen species (ROS) in cellular compartments that eventually leads to activation of autophagic, apoptotic and necrotic death pathways. In this review, we summarized the recent advancements in the biosynthesis of Ag, Au, Zn and Cu NPs with emphasis on their mechanism of action. Moreover, nanotoxicity, as well as the future prospects and opportunities of nano-therapeutics, are also highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 1×
“Owing to effectiveness of this therapy, several studies have been reported to block signaling of VEGF, PDGF, EDGR, angiopoietin- key contributors of neovascularization [61].”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“It has been reported previously that positive groups like primary amine present at the surface of polystyrene microparticles helped in faster internalization in cells as compared to the microparticles, which contained hydroxyl, sulfate or carboxyl as surface groups [52].”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 1×
“Cancer cells display abnormal membrane structure because of enhanced blood vasculature due to upregulated expression of angiogenic factors [58,59].”
BackgroundRegulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Current Challenges of Cancer Anti-angiogenic Therapy and the Promise of Nanotherapeutics
Abdalla, A. M. E., Xiao, L., Ullah, M. W., Yu, M., Ouyang, C., & Yang, G. (2018) · Theranostics · doi:10.7150/thno.21674 · Cited by 240
Anti-cancer green bionanomaterials: present status and future prospects
Barabadi, H., Ovais, M., Shinwari, Z. K., & Saravanan, M. (2017) · Green Chemistry Letters and Reviews · doi:10.1080/17518253.2017.1385856 · Cited by 221 · cited 1×
“In recent years, optimal methods for metallic NPs preparations with anti-cancer properties are widely being examined both in vivo and in vitro [72].”
Background
Cited by
Plant-Based Green Synthesis of Nanoparticles: Production, Characterization and Applications
Hano, C., & Abbasi, B. H. (2021) · Biomolecules · doi:10.3390/biom12010031 · Cited by 469
Self-citationSidhu, A. K., Verma, N., & Kaushal, P. (2022) · Frontiers in Nanotechnology · doi:10.3389/fnano.2021.801620 · Cited by 418
Burlec, A. F., Corciova, A., Boev, M., Batir-Marin, D., Mircea, C., Cioanca, O., Danila, G., Danila, M., Bucur, A. F., & Hancianu, M. (2023) · Pharmaceuticals · doi:10.3390/ph16101410 · Cited by 295
Bharadwaj, K. K., Rabha, B., Pati, S., Sarkar, T., Choudhury, B. K., Barman, A., Bhattacharjya, D., Srivastava, A., Baishya, D., Edinur, H. A., et al. (2021) · Molecules · doi:10.3390/molecules26216389 · Cited by 284
Metadata
- Authors
- Andleeb, A., Andleeb, A., Asghar, S., Zaman, G., Tariq, M., Mehmood, A., Nadeem, M., Hano, C., Lorenzo, J. M., & Abbasi, B. H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2021-06-05
- Volume
- 13
- Issue
- 11
- Pages
- 2818
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3170186537
- Cited by
- 170
- References
- 8
- FWCI
- 1.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.